Latest Insider Transactions at Viela Bio, Inc. (VIE)
This section provides a real-time view of insider transactions for Viela Bio, Inc. (VIE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Viela Bio, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Viela Bio, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2021
|
Astrazeneca PLC > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
14,650,334
-100.0%
|
$776,467,702
$53.0 P/Share
|
|
Mar 13
2021
|
Yanling Cao Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
8,322,353
-100.0%
|
$441,084,709
$53.0 P/Share
|
|
Mar 13
2021
|
Zhengbin Yao Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
200,000
-100.0%
|
$10,600,000
$53.0 P/Share
|
|
Mar 13
2021
|
Zhengbin Yao Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
270,219
-100.0%
|
$14,321,607
$53.0 P/Share
|
|
Mar 13
2021
|
William Ragatz Senior VP, Head of Commercial |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,250
-100.0%
|
$861,250
$53.0 P/Share
|
|
Mar 13
2021
|
Jorn Drappa Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
202,661
-100.0%
|
$10,741,033
$53.0 P/Share
|
|
Mar 13
2021
|
Mitchell Chan Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
37,500
-100.0%
|
$1,987,500
$53.0 P/Share
|
|
Mar 13
2021
|
Boundless Meadow LTD > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
300,000
-100.0%
|
$15,900,000
$53.0 P/Share
|
|
Mar 13
2021
|
Boundless Meadow LTD > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
8,322,353
-100.0%
|
$441,084,709
$53.0 P/Share
|
|
Mar 13
2021
|
Edward Hu Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
4,161,177
-100.0%
|
$220,542,381
$53.0 P/Share
|
|
Mar 13
2021
|
Andreas Wicki Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,750,000
-100.0%
|
$92,750,000
$53.0 P/Share
|
|
Nov 18
2020
|
Aaron Ren Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.73%
|
$4,000
$2.84 P/Share
|
|
Oct 07
2019
|
Astrazeneca PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
425,000
+2.82%
|
$8,075,000
$19.0 P/Share
|
|
Oct 07
2019
|
Astrazeneca PLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
14,225,324
+50.0%
|
-
|